<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00476099</url>
  </required_header>
  <id_info>
    <org_study_id>DM/PR/033011/005/05</org_study_id>
    <secondary_id>2006-002489-20</secondary_id>
    <nct_id>NCT00476099</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD</brief_title>
  <official_title>A 48-week, Double Blind, Double Dummy, Randomised, Multinational, Multicentre, 3-arm Parallel Group Clinical Study of &quot;Fixed Combination&quot; Beclometasone Dipropionate Plus Formoterol Fumarate Administered Via pMDI With HFA-134a Propellant Versus &quot;Fixed Combination&quot; Budesonide Plus Formoterol DPI Versus Formoterol DPI in Patients With Stable Severe Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the 1-year efficacy and safety of the fixed combination beclometasone/formoterol
      pMDI in a twice daily regimen in patients with stable severe COPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the long-term efficacy and safety of the fixed
      combination beclometasone/formoterol pMDI in a twice daily regimen in patients with stable
      severe COPD. Patients are randomised to receive either beclometasone/formoterol or
      budesonide/formoterol DPI or formoterol DPI during 48 weeks of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of COPD exacerbations and pre-dose morning FEV1</measure>
    <time_frame>one year treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other pulmonary function parameters,</measure>
    <time_frame>one year treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD symptom scores and Quality of Life,</measure>
    <time_frame>one year treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability</measure>
    <time_frame>one year treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">828</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide 200 µg plus formoterol 6 µg DPI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol 12 µg DPI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI</intervention_name>
    <description>Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) two puffs via oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.</description>
    <arm_group_label>Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI</arm_group_label>
    <arm_group_label>Budesonide 200 µg plus formoterol 6 µg DPI</arm_group_label>
    <arm_group_label>Formoterol 12 µg DPI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide 200 µg plus formoterol 6 µg DPI</intervention_name>
    <description>two oral inhalations twice a day at 8.00 a.m. and 8.00 p.m.</description>
    <arm_group_label>Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI</arm_group_label>
    <arm_group_label>Budesonide 200 µg plus formoterol 6 µg DPI</arm_group_label>
    <arm_group_label>Formoterol 12 µg DPI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol 12 µg DPI</intervention_name>
    <description>one oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.</description>
    <arm_group_label>Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI</arm_group_label>
    <arm_group_label>Budesonide 200 µg plus formoterol 6 µg DPI</arm_group_label>
    <arm_group_label>Formoterol 12 µg DPI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of COPD (according to GOLD guidelines)

          -  FEV1 &gt; or equal 30% and &lt; 50% of predicted normal post-bronchodilator (and at least
             0.7 L absolute value)

          -  COPD symptoms for at least 2 years

          -  At least 1 exacerbation requiring medical intervention (oral corticosteroid and/or
             antibiotic treatment and/or need for a visit to an emergency department and/or
             hospitalization) within 2-12 months before screening

          -  Current or previous smoker with a cumulative exposure to smoke of more than 20-pack
             year

        Exclusion Criteria:

          -  Current or past diagnosis of asthma, or any evidence suggestive of asthma

          -  Positive FEV1 reversibility test

          -  Clinically significant or unstable concurrent diseases, including clinically
             significant laboratory abnormalities

          -  Acute COPD exacerbation or lower tract infection and/or treatment with oral or
             injectable corticosteroids and antibiotics in the 2 months before screening or during
             run-in

          -  Long term oxygen therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter M.A. Calverley, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Clinical Sciences Center University Hospital Aintree, Liverpool, United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Similowski</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002489-20</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <results_reference>
    <citation>Calverley PM, Kuna P, Monsó E, Costantini M, Petruzzelli S, Sergio F, Varoli G, Papi A, Brusasco V. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir Med. 2010 Dec;104(12):1858-68. doi: 10.1016/j.rmed.2010.09.008. Epub 2010 Oct 20.</citation>
    <PMID>20965712</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2007</study_first_submitted>
  <study_first_submitted_qc>May 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2007</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

